Pharmacy benefit managers defended their roles in a Congressional hearing amid accusations of promoting expensive treatments. Executives claimed their models save money, while a report highlighted anti-competitive practices and high drug prices.
US pharmaceutical industry intermediaries defend their role
Original Article by Amina Niasse & Bhanvi Satija | Reuters | 23 July 2024
Pharmacy benefit managers defended their roles in a Congressional hearing amid accusations of promoting expensive treatments. Executives claimed their models save money, while a report highlighted anti-competitive practices and high drug prices.
More Posts
Mpox Cases in SA Rise as Local Transmission Accelerates
Mpox cases in South Africa are rising, mainly in the Western Cape. What the surge means for the healthcare industry.
Read more...
NHLS Scrambles as Pathology Services Funding Runs Dry
The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt
Read more...
Momentum Group Posts Record Earnings
Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.
Read more...